(redirected from Temodar)
Also found in: Dictionary.
Related to Temodar: Tramadol, Avastin, Temodal


a cytotoxic alkylating agent used as an antineoplastic in the treatment of refractory anaplastic astrocytoma, administered orally.


Temodal, Temodar

Pharmacologic class: Alkylating agent

Therapeutic class: Antineoplastic

Pregnancy risk category D


Rapidly converts to monomethyl triazeno imidazole carboxamide, an active compound that prevents DNA transcription


Capsules: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, 250 mg

Injection (powder for solution, lyophilized): 100 mg

Indications and dosages

Refractory anaplastic astrocytoma

Adults: 150 mg/m2 P.O. or by 90-minute I.V. infusion daily for 5 consecutive days of each 28-day treatment cycle. Adjust dosage as appropriate based on absolute neutrophil count.

Newly diagnosed glioblastoma multiforme with radiotherapy

Adults: 75 mg/m2 P.O. or by 90-minute I.V. infusion for 42 days with focal radiotherapy (RT), followed by initial maintenance dose of 150 mg/m2 P.O. or by 90-minute I.V. infusion daily for days 1 to 5 of a 28-day cycle for six cycles. Four weeks after completing the drug plus RT phase, administer drug for an additional six cycles of maintenance treatment. Dosage in maintenance cycle 1 is 150 mg/m2 P.O. or by 90-minute I.V. infusion daily for 5 days, followed by 23 days without treatment. At start of maintenance cycle 2, dosage may be escalated to 200 mg/m2 based on absolute neutrophil and platelet counts. Continue dosage at 200 mg/m2 daily for first 5 days of each subsequent cycle except if toxicity occurs. If dosage wasn't escalated at maintenance cycle 2, escalation shouldn't be done in subsequent cycles.

Dosage adjustment

• Neutropenia, thrombocytopenia


• Hypersensitivity to drug, its components, or dacarbazine


Use cautiously in:

• severe hepatic or renal impairment, active infection, decreased bone marrow reserve, other chronic debilitating illness

• elderly patients

• pregnant or breastfeeding patients

• children (safety not established).


• Follow facility policy for handling and disposing of chemotherapeutic drugs.

• Give capsules whole daily with a full glass of water, consistently either with or without food.

• Bring powder for injection to room temperature before reconstituting with 41 ml sterile water for injection that results in a 2.5-mg/ml solution. Gently swirl but don't shake vials. Don't further dilute reconstituted solution. Use reconstituted solution within 14 hours, including infusion time. Withdraw prescribed dose and transfer into empty 250-ml infusion bag. Give reconstituted solution only by I.V. infusion using infusion pump over 90 minutes. Flush lines before and after each infusion.

• Know that drug may be given in same I.V. line with normal saline solution for injection only.

• Be aware that dosages in 28-day cycle depend on nadir neutrophil and platelet counts.

Adverse reactions

CNS: fatigue, headache, dysphasia, poor coordination, ataxia, anxiety, depression, dizziness, drowsiness, confusion, amnesia, insomnia, mental status changes, weakness, paresis, hemiparesis, paresthesias, seizures

CV: peripheral edema

EENT: abnormal vision, diplopia, pharyngitis, sinusitis

GI: nausea, vomiting, constipation, diarrhea, abdominal pain, anorexia

GU: urinary incontinence or frequency, urinary tract infection, breast pain (in women)

Hematologic: anemia, leukopenia, thrombocytopenia

Metabolic: adrenal hypercorticism

Musculoskeletal: abnormal gait, back pain, myalgia

Respiratory: cough, upper respiratory infection

Skin: pruritus, rash

Other: fever, viral infection, weight gain


Drug-drug. Antineoplastics: additive bone marrow depression

Live-virus vaccines: decreased antibody response to vaccine, greater risk of adverse reactions

Valproic acid: decreased oral clearance of temozolomide

Drug-diagnostic tests. Neutrophils, platelets: decreased counts

Drug-food. Any food: reduced rate and extent of temozolomide absorption

Patient monitoring

Monitor CBC with white cell differential. Stay alert for evidence of bone marrow depression.

• Assess neurologic status carefully.

• Monitor fluid intake and output, and weigh patient regularly.

• Be aware that Pneumocystis jiroveci pneumonia prophylaxis is required during concomitant administration of RT and should be continued in patients who develop lymphocytopenia until recovery from lymphocytopenia (circulating tumor cells Grade 1 or less).

Patient teaching

• Tell patient to take capsules consistently with or without food, and with a full glass of water.

• Instruct patient to swallow capsules whole without opening or chewing them and if capsules are accidentally opened or damaged, to avoid inhalation or contact with the skin or mucous membranes.

• If drug causes nausea or vomiting, advise patient to take it 1 hour before or 2 hours after a meal.

• Inform patient that drug may cause abnormal gait and dizziness.

Instruct patient to immediately report unusual bleeding or bruising.

• Advise patient to avoid live-virus vaccines.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, alertness, and vision.

• Instruct patient to report suspected pregnancy. Caution her not to breastfeed.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.


/tem·o·zo·lo·mide/ (tem″ah-zo´lah-mīd) a cytotoxic alkylating agent used as an antineoplastic in the treatment of refractory anaplastic astrocytoma.


a miscellaneous antineoplastic agent.
indication It is used to treat anaplastic astrocytoma with relapse.
contraindications Pregnancy, lactation, and known hypersensitivity to this drug or to carbazine prohibit its use.
adverse effects Life-threatening effects are thrombocytopenia, leukopenia, and seizures. Other adverse effects include anemia, urinary incontinence, urinary tract infection, urinary frequency, upper respiratory infection, pharyngitis, sinusitis, cough, headache, fatigue, asthenia, fever, edema, back pain, weight increase, and diplopia. Common side effects include nausea, anorexia, vomiting, hemiparesis, dizziness, poor coordination, amnesia, insomnia, paresthesia, somnolence, paresis, ataxia, anxiety, dysphagia, depression, confusion, rash, and pruritus.


Temodal® Oncology An alkylating agent used for recurrent gliomas–eg, anaplastic astrocytoma, and possibly melanoma and other solid tumors. See Astrocytoma, Glioblastoma multiforme.
References in periodicals archive ?
She received Fluorouracil (5FU) and Temodar and refused radiation.
This product is Mylan's generic version of Merck's Temodar.
In March of 2010, Teva agreed to hold off on launching a generic version of Temodar until a federal appeals court made a decision.
To settle civil False Claims Act liabilities, Schering-Plough will pay $255 million for misreporting its best price of Claritin RediTabs and K-Dur to avoid paying Medicaid rebates (thereby overcharging Public Health Service programs); paying physicians to prescribe Intron A and Temodar; and promoting Temodar for certain brain tumors and brain metastases and Intron A for superficial bladder cancer--off-label uses not approved by the FDA.
In one preclinical study, daily oral administration of 2ME2 in combination with a maximally tolerated course of Temodar (temozolomide) resulted in 87% growth inhibition of advanced glioblastoma (brain cancer).
Temozolomide, marketed as Temodar in the United States and Temodal in Europe, has been available for many years.
Temozolomide, marketed as Temodar in the United States and Temodal in Europe, has been available for many years, it is an alkylating and methylating agent that causes small DNA breaks that ultimately result in depletion of repair enzymes in tumor cells.
It is a small molecule that has shown potent inhibitory activity against a broad panel of brain tumor cell lines, including cells (T98G) that are resistant to Temodar, the most widely used chemotherapy for the treatment of malignant glioma.
The company added Temozolomide Capsules 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg is the therapeutic equivalent to the reference listed drug Temodar Capsules of Merck & Co.
loss of market exclusivity for several products, including Temodar, a
Last week, the Journal of Clinical Oncology published a report showing that glioblastoma patients who received CDX-110 in addition to surgery, radiation treatment, and the cancer drug Temodar lived longer than patients who only received surgery, radiation, and Temodar.
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.